Recently, we have developed a potent SARS-CoV-2 neutralizing human mAb HB27, which targets the receptor binding domain (RBD) of spike (S) protein,15 and the therapeutic efficacy against mild or moderated COVID-19 patients are being evaluated in phase II clinical trials (NCT04644185). The gene discussed is PROS1; the disease is COVID-19.